Sensorium Therapeutics
Dick Simon is a Co-Founder and Member at Sensorium Therapeutics, serving as the CEO and on the Board of Directors since June 2021. Additionally, Dick is involved in various organizations such as the Psychedelic Science Funders Collaborative, Massachusetts General Hospital, Boston Psychedelic Research Group, YPO Psychedelic Medicines for Mental Health Group, and kNOwTHEM Initiative. Dick is also the Co-Founder and Chairman of the YPO Peace Action Network and serves as CEO of RSI. With a background in History from Cornell University and an MBA from Harvard Business School, Dick has been actively engaged in leadership roles that go beyond business and focus on community engagement and awareness.
Sensorium Therapeutics
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world.